Bile secretion is a major function of the liver which is frequently impaired in diseases of the liver resulting in the syndrome of cholestasis. The long term objectives of this grant application, funded continuously since 1973, have been to characterize the basic transport mechanisms in hepatocytes that determine the secretion of bile and to define at the cellular and molecular level, alterations in these mechanisms that result in cholestatic liver disease. In this competitive renewal proposal the specific aims are #1. To understand the molecular mechanisms for adaptive regulation of basolateral hepatocyte membrane transporters (specifically MRP4 and OST1-OST2) in human liver that are important determinants of the adaptive response in cholestatic liver injury and to devise new therapies based on this information. In particular we will attempt to characterize the transcriptional regulators of the human MRP4 promoter as well as to continue to assess the role of OST2 in the adaptive regulation of the human heteromeric, facilitated bile salt transporter, OST1-OST2, and to determine the effect of bile duct ligation in the Ost1 knock out mice. In order to examine new therapeutic approaches we will assess the synergistic therapeutic effects of the combination of all-trans retinoic acid + ursodeoxycholic acid on human transporter gene expression in HepG2 cells and in animal models of cholestasis.
In Aim # 2. we will examine the determinants by which the expression of the bile salt export pump (Bsep) is regulated in normal and cholestatic liver injury by focusing on the role of the ubiquitin/proteasome degradation pathway as a determinant of the regulation of surface expression of Bsep. Finally in Aim # 3. we will investigate the functional roles of proteins involved in maintaining canalicular apical membrane structural polarity. To do this we will determine the role of scaffolding proteins in the targeting and regulation of the ABC transporter, Mrp2. We will also assess the role of FIC1 in the regulation of human FXR expression and activity in human cell lines and rat hepatocytes by knocking down Fic1 using siRNA, as well as determining the role of Fic1 in maintaining canalicular structure and Bsep and Mrp2 function in rat collagen sandwich hepatocyte cultures. Public Health Relevance Narrative: This grant application supports research that focuses on understanding how the liver adapts to injury resulting from impairment of bile production (known as cholestasis). Bile formation is a vital function and its impairment in a variety of cholestatic liver diseases often results in progressive cholestasis and liver failure that can result in death or liver transplantation. By understanding the mechanism of adaptations of bile transporter proteins at the cellular and molecular level in cholestatic liver injury, we hope to design new therapeutic strategies that will augment these adaptive responses and retard or reverse the progression of these potentially fatal liver disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37DK025636-33
Application #
7637942
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Serrano, Jose
Project Start
1978-09-01
Project End
2013-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
33
Fiscal Year
2009
Total Cost
$931,545
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Yu, Dongke; Cai, Shi-Ying; Mennone, Albert et al. (2018) Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 38:1128-1138
Pan, Qiong; Zhang, Xiaoxun; Zhang, Liangjun et al. (2018) Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 155:1578-1592.e16
Yu, Dongke; Zhang, Han; Lionarons, Daniel A et al. (2017) Na+-taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate Leucoraja erinacea is not a physiological bile salt transporter. Am J Physiol Regul Integr Comp Physiol 312:R477-R484
Li, Man; Cai, Shi-Ying; Boyer, James L (2017) Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med 56:45-53
Cai, Shi-Ying; Boyer, James L (2017) Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal 4:
Cai, Shi-Ying; Boyer, James L (2017) The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage. Dig Dis 35:232-234
Cai, Shi-Ying; Ouyang, Xinshou; Chen, Yonglin et al. (2017) Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight 2:e90780
Xu, Shuhua; Soroka, Carol J; Sun, An-Qiang et al. (2016) A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization. PLoS One 11:e0158269
Kulkarni, Supriya R; Soroka, Carol J; Hagey, Lee R et al. (2016) Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology 64:2151-2164
Chai, Jin; Cai, Shi-Ying; Liu, Xiaocong et al. (2015) Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. J Hepatol 63:1440-8

Showing the most recent 10 out of 153 publications